Kymera Therapeutics, Inc. Common Stock
KYMRKymera Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapies to treat serious diseases. Using its proprietary Pegasus platform, the company designs small molecules to selectively degrade disease-causing proteins, aiming to address previously "undruggable" targets in areas such as inflammation, oncology, and genetic disorders. Founded to leverage novel approaches in drug discovery, Kymera aims to transform medicine through innovative targeted degradation strategies.
Company News
Kymera Therapeutics announced its 2026 clinical and preclinical milestones, including ongoing Phase 2b trials for KT-621 in atopic dermatitis and asthma with data expected in 2027, initiation of Phase 1 testing for KT-579 in Q1 2026, and advancement of at least one new development candidate toward IND. The company maintains $1.6 billion in cash w...
Three stocks have attracted over $100 million in insider buying from prominent institutional investors: DoorDash (Sequoia Capital), Kenvue (Starboard Value LP), and Kymera Therapeutics (Baker Bros. Advisors). While these purchases signal confidence from sophisticated capital, investors should consider offsetting insider sales and the long-term vi...
Kymera Therapeutics successfully closed a public offering of $602 million, selling 8,050,000 shares at $86.00 per share, including the full exercise of underwriters' option to purchase additional shares.
Kymera Therapeutics plans to raise $602 million through a public offering of 7 million common stock shares at $86 per share, with proceeds intended to advance its preclinical and clinical degrader programs.
Kymera Therapeutics initiated dosing in its BROADEN2 Phase 2b clinical trial for KT-621, an oral STAT6 degrader targeting moderate to severe atopic dermatitis. The company expects to report trial data by mid-2027 and is also preparing for a Phase 2b asthma trial in early 2026.
